JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB103547

Anti-CYP2C8 antibody

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Polyclonal CYP2C8 antibody. Carrier free. Suitable for WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human Cytochrome P450 2C8.

View Alternative Names

Cytochrome P450 2C8, CYPIIC8, Cytochrome P450 IIC2, Cytochrome P450 MP-12, Cytochrome P450 MP-20, Cytochrome P450 form 1, S-mephenytoin 4-hydroxylase, CYP2C8

2 Images
Western blot - Anti-CYP2C8 antibody (AB103547)
  • WB

Unknown

Western blot - Anti-CYP2C8 antibody (AB103547)

All lanes:

Western blot - Anti-CYP2C8 antibody (ab103547) at 1/500 dilution

All lanes:

Human liver tissue lysate at 50 µg

Predicted band size: 56 kDa

false

Western blot - Anti-CYP2C8 antibody (AB103547)
  • WB

Unknown

Western blot - Anti-CYP2C8 antibody (AB103547)

All lanes:

Western blot - Anti-CYP2C8 antibody (ab103547) at 1/500 dilution

Lane 1:

CYP2C8 transfected 293T cell lysate at 25 µg

Lane 2:

Non-transfected 293T cell lysate at 25 µg

Predicted band size: 56 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

Yes

Reacts with

Human

Applications

WB

applications

Immunogen

Recombinant Full Length Protein corresponding to Human Cytochrome P450 2C8.

P10632

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/1000", "WB-species-notes": "<p></p>" } } }
style
left-column
style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CYP2C8 also known as Cytochrome P450 2C8 is a member of the cytochrome P450 superfamily of enzymes. It has a molecular mass of approximately 56 kDa. CYP2C8 localizes mainly in the liver but can be found in smaller amounts in other tissues such as the kidney and heart. This enzyme plays a role in oxidizing various substances impacting drug metabolism. The enzyme achieves this by catalyzing reactions involved in drug detoxification and steroid synthesis.
Biological function summary

CYP2C8 facilitates the metabolism of xenobiotics and endogenous compounds contributing to homeostasis. It forms part of the cytochrome P450 hepatic microsomal enzyme complex which contains multiple enzymes responsible for oxidative metabolism. CYP2C8 metabolizes several clinically important drugs including paclitaxel and amodiaquine as well as endogenous arachidonic acid impacting vascular biology.

Pathways

This enzyme acts within the drug metabolism and arachidonic acid metabolism pathways. Within these pathways it works closely with other cytochrome P450 enzymes such as CYP3A4. The drug metabolism pathway requires CYP2C8 for phase I of drug processing which modifies drugs into more water-soluble compounds. In arachidonic acid metabolism CYP2C8 is important to forming bioactive epoxyeicosatrienoic acids that function as signaling molecules in tissues.

Dysregulation of CYP2C8 activity relates to conditions such as drug-induced liver injury and cardiovascular diseases. Variants in the CYP2C8 gene can lead to altered enzyme activity influencing drug response and toxicity. Furthermore its interaction with CYP2C9 in pharmacogenomic variability can affect patients' susceptibility to adverse drug reactions emphasizing the role in personalized medicine approaches.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed : 11093772, PubMed : 14559847, PubMed : 15766564, PubMed : 19965576, PubMed : 7574697). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed : 11093772, PubMed : 14559847, PubMed : 15766564, PubMed : 19965576, PubMed : 7574697). Primarily catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) with a preference for the last double bond (PubMed : 15766564, PubMed : 19965576, PubMed : 7574697). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes all trans-retinoic acid toward its 4-hydroxylated form (PubMed : 11093772). Displays 16-alpha hydroxylase activity toward estrogen steroid hormones, 17beta-estradiol (E2) and estrone (E1) (PubMed : 14559847). Plays a role in the oxidative metabolism of xenobiotics. It is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel (taxol) (PubMed : 26427316).
See full target information Cytochrome P450 2C8
style
left-column

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

BMC medical genomics 16:5 PubMed36635662

2023

Disruption of DDX53 coding sequence has limited impact on iPSC-derived human NGN2 neurons.

Applications

Unspecified application

Species

Unspecified reactive species

Muhammad Faheem,Eric Deneault,Roumiana Alexandrova,Deivid C Rodrigues,Giovanna Pellecchia,Carole Shum,Mehdi Zarrei,Alina Piekna,Wei Wei,Jennifer L Howe,Bhooma Thiruvahindrapuram,Sylvia Lamoureux,P Joel Ross,Clarrisa A Bradley,James Ellis,Stephen W Scherer
View all publications
style
left-column
style
left-column
style
right-column

Alternative Products

Primary Antibodies

AB88904

Anti-CYP2C8 antibody

Western blot - Anti-CYP2C8 antibody (AB88904)

  • 0
  • 0

Complementary Products

Primary Antibodies

AB4236

Anti-CYP2C9 antibody

BOND RX™ Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2C9 antibody (AB4236)

  • 5
  • 2
Primary Antibodies

AB151728

Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]

RabMAb|Recombinant

Immunocytochemistry/ Immunofluorescence - Anti-Cytochrome P450 1A2 antibody [EPR6138(2)] (AB151728)

  • 0
  • 0
Primary Antibodies

AB140609

Anti-Cytochrome P450 2B6/CYP2B6 antibody [EPR9985(B)]

RabMAb|Recombinant

Western blot - Anti-Cytochrome P450 2B6/CYP2B6 antibody [EPR9985(B)] (AB140609)

  • 1
  • 1
Primary Antibodies

AB108624

Anti-CYP3A5 antibody [EPR4396]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com